Christina I. Herold

1.8k total citations · 1 hit paper
26 papers, 1.3k citations indexed

About

Christina I. Herold is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Christina I. Herold has authored 26 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 11 papers in Genetics. Recurrent topics in Christina I. Herold's work include Estrogen and related hormone effects (9 papers), Advanced Breast Cancer Therapies (8 papers) and Breast Cancer Treatment Studies (8 papers). Christina I. Herold is often cited by papers focused on Estrogen and related hormone effects (9 papers), Advanced Breast Cancer Therapies (8 papers) and Breast Cancer Treatment Studies (8 papers). Christina I. Herold collaborates with scholars based in United States, France and Belgium. Christina I. Herold's co-authors include P. Kelly Marcom, Matthew S. Marengo, Daniel J. George, Sebastian Oltean, James Turnbull, Andrew J. Armstrong, Gabor Kemeny, Mariano A. García-Blanco, Rhonda L. Bitting and Nadine Tung and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Christina I. Herold

25 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers

2011 536 citations Andrew J. Armstrong, Matthew S. Marengo et al. Molecular Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christina I. Herold United States	11	770	461	388	325	264	26	1.3k
Ossi R. Köchli Switzerland	10	861 1.1×	552 1.2×	773 2.0×	185 0.6×	247 0.9×	44	1.8k
Paul J. van Diest Netherlands	22	549 0.7×	454 1.0×	833 2.1×	177 0.5×	184 0.7×	40	1.6k
Luan Nguyen Netherlands	9	501 0.7×	386 0.8×	432 1.1×	121 0.4×	188 0.7×	14	913
Bonnie L. King United States	19	605 0.8×	361 0.8×	465 1.2×	117 0.4×	128 0.5×	36	1.2k
Kim A. Reiss United States	19	971 1.3×	444 1.0×	452 1.2×	109 0.3×	226 0.9×	63	1.4k
Heather Thorne Australia	18	1.1k 1.4×	761 1.7×	1.2k 3.1×	568 1.7×	370 1.4×	40	2.2k
Cathy B. Moelans Netherlands	28	917 1.2×	719 1.6×	1.0k 2.6×	433 1.3×	386 1.5×	87	2.1k
Stefanie Avril United States	22	801 1.0×	418 0.9×	649 1.7×	101 0.3×	189 0.7×	45	1.7k
Kenta Kawasaki Japan	14	1.1k 1.4×	413 0.9×	516 1.3×	101 0.3×	169 0.6×	37	1.6k
Therese Törngren Sweden	15	605 0.8×	313 0.7×	555 1.4×	295 0.9×	154 0.6×	26	1.1k

Countries citing papers authored by Christina I. Herold

Since Specialization

Citations

This map shows the geographic impact of Christina I. Herold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christina I. Herold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christina I. Herold more than expected).

Fields of papers citing papers by Christina I. Herold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christina I. Herold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christina I. Herold. The network helps show where Christina I. Herold may publish in the future.

Co-authorship network of co-authors of Christina I. Herold

This figure shows the co-authorship network connecting the top 25 collaborators of Christina I. Herold. A scholar is included among the top collaborators of Christina I. Herold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christina I. Herold. Christina I. Herold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garrido-Castro, Ana C., Noah Graham, Lestat R. Ali, et al.. (2025). Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer. Journal for ImmunoTherapy of Cancer. 13(2). e010430–e010430. 5 indexed citations

Campone, Mario, François‐Clément Bidard, Patrick Neven, et al.. (2023). AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer. Breast Cancer Research. 25(1). 141–141. 3 indexed citations

Edwards, Teresa, Jennifer Fine, Susan Martin, et al.. (2023). Side effects and impacts of extended adjuvant endocrine therapy: A qualitative study among women with HR+/HER2- breast cancer.. Journal of Clinical Oncology. 41(16_suppl). e12509–e12509. 1 indexed citations

Metzger, Otto, Christina I. Herold, Coralie Poncet, et al.. (2023). Abstract OT1-04-01: AMEERA-6: Phase 3 Study of Adjuvant Amcenestrant Versus Tamoxifen for Patients With Hormone Receptor-Positive Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity. Cancer Research. 83(5_Supplement). OT1–4. 3 indexed citations

Rossi, Giovanna, Étienne Brain, Amylou C. Dueck, et al.. (2022). 90TiP Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6). Annals of Oncology. 33. S162–S163. 1 indexed citations

Campone, Mario, et al.. (2021). Abstract OT-09-11: AMEERA-4, a phase 2 window study of SAR439859 vs letrozole in post-menopausal women with newly diagnosed estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Cancer Research. 81(4_Supplement). OT–9. 1 indexed citations

Herold, Christina I., Lorenzo Trippa, Tianyu Li, et al.. (2020). Abstract P3-14-03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR+ MBC) and metastatic ovarian cancer (MOC). Cancer Research. 80(4_Supplement). P3–14. 10 indexed citations

Campone, Mario, et al.. (2020). Phase II preoperative window study of SAR439859 versus letrozole in post-menopausal women with newly diagnosed estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.. Journal of Clinical Oncology. 38(15_suppl). TPS1108–TPS1108. 5 indexed citations

Wagner, Andrew J., et al.. (2018). Improving efficiency of exam room use at a comprehensive cancer center.. Journal of Clinical Oncology. 36(30_suppl). 307–307. 1 indexed citations

10.

Herold, Christina I., Wenjie Luo, Richard T. Penson, et al.. (2018). A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer. Annals of Oncology. 29. viii334–viii335. 20 indexed citations

11.

Mamtani, Anita, Priscilla J. Slanetz, Mary Jane Houlihan, et al.. (2016). Early-Stage Breast Cancer in the Octogenarian: Tumor Characteristics, Treatment Choices, and Clinical Outcomes. Annals of Surgical Oncology. 23(10). 3371–3378. 24 indexed citations

12.

Bychkovsky, Brittany, Kathrin Strasser‐Weippl, Christina I. Herold, et al.. (2015). Cervical cancer control in Latin America: A call to action. Cancer. 122(4). 502–514. 30 indexed citations

13.

Herold, Christina I., Vijaya Chadaram, Bercedis L. Peterson, et al.. (2011). Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing. Clinical Cancer Research. 17(18). 6061–6070. 64 indexed citations

14.

Armstrong, Andrew J., Matthew S. Marengo, Sebastian Oltean, et al.. (2011). Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers. Molecular Cancer Research. 9(8). 997–1007. 536 indexed citations breakdown →

15.

Herold, Christina I., Cristina Gasparetto, & Gowthami M. Arepally. (2011). Lenalidomide-Associated ITP. SHILAP Revista de lepidopterología. 2011. 1–4. 5 indexed citations

16.

Herold, Christina I., Elizabeth M Gaughan, Carolyn C. Lamb, & Nadine Tung. (2011). Second Primary Ipsilateral Breast Cancer With Contralateral Axillary Involvement: A Case Report and Literature Review. Clinical Breast Cancer. 11(6). 406–408. 12 indexed citations

17.

Herold, Christina I., Benjamin Djulbegović, Iztok Hozo, & Gary H. Lyman. (2009). Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. Breast Cancer Research and Treatment. 121(3). 771–776. 2 indexed citations

18.

Herold, Christina I. & Kimberly Blackwell. (2008). Aromatase Inhibitors for Breast Cancer: Proven Efficacy Across the Spectrum of Disease. Clinical Breast Cancer. 8(1). 50–64. 21 indexed citations

19.

Herold, Christina I. & Kimberly Blackwell. (2008). The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. The Breast. 17. S15–S24. 4 indexed citations

20.

Herold, Christina I. & P. Kelly Marcom. (2008). Primary Systemic Therapy in Breast Cancer: Past Lessons and New Approaches. Cancer Investigation. 26(10). 1052–1059. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact